$AMLX
Amylyx Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024465 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $21.89M $345.0K $285.0K
YoY Change 21.05% -5.0%
Cost Of Revenue $2.821M $172.0K
YoY Change
Gross Profit $19.06M $173.0K
YoY Change
Gross Profit Margin 87.11% 50.14%
Selling, General & Admin $40.84M $29.94M $24.01M
YoY Change 173.74% 24.69% 115.74%
% of Gross Profit 214.25% 17306.36%
Research & Development $22.81M $24.91M $30.65M
YoY Change 70.32% -18.7% 56.52%
% of Gross Profit 119.67% 14401.16%
Depreciation & Amortization $182.0K $165.0K $10.00K
YoY Change 727.27% 1550.0%
% of Gross Profit 0.95% 95.38%
Operating Expenses $63.66M $54.85M $54.66M
YoY Change 124.82% 0.36% 77.98%
Operating Profit -$44.59M -$54.68M -$22.92M
YoY Change 138.59%
Interest Expense $3.157M $601.0K $6.000K
YoY Change 10423.33% 9916.67% -100.17%
% of Operating Profit
Other Income/Expense, Net -$689.0K $800.0K -$5.220M
YoY Change 1067.8% -115.33% -2033.33%
Pretax Income -$42.13M -$53.88M -$59.59M
YoY Change 48.62% -9.58% 76.87%
Income Tax $579.0K -$125.0K
% Of Pretax Income
Net Earnings -$42.70M -$53.76M -$59.59M
YoY Change 50.66% -9.79% 76.87%
Net Earnings / Revenue -195.13% -15581.45% -20907.72%
Basic Earnings Per Share -$0.92 -$3.42
Diluted Earnings Per Share -$0.65 -$0.92 -$1.055M
COMMON SHARES
Basic Shares Outstanding 66.26M 58.53M 6.757M
Diluted Shares Outstanding 58.53M 6.757M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $346.9M $162.6M $125.7M
YoY Change 260.96% 29.35%
Cash & Equivalents $62.53M $107.7M $76.68M
Short-Term Investments $284.4M $54.86M $49.03M
Other Short-Term Assets $10.11M $8.906M $4.240M
YoY Change 14.49% 110.05%
Inventory $9.769M $563.0K
Prepaid Expenses
Receivables $15.31M $137.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $382.1M $172.2M $129.9M
YoY Change 264.11% 32.52%
LONG-TERM ASSETS
Property, Plant & Equipment $2.611M $2.118M $329.0K
YoY Change 450.84% 543.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $466.0K $456.0K $189.0K
YoY Change 146.56% 141.27%
Total Long-Term Assets $9.320M $9.244M $518.0K
YoY Change 1305.73% 1684.56%
TOTAL ASSETS
Total Short-Term Assets $382.1M $172.2M $129.9M
Total Long-Term Assets $9.320M $9.244M $518.0K
Total Assets $391.5M $181.4M $130.5M
YoY Change 270.64% 39.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.257M $7.052M $3.026M
YoY Change 43.12% 133.05%
Accrued Expenses $40.35M $25.60M $11.86M
YoY Change 209.83% 115.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $263.0K
YoY Change
Total Short-Term Liabilities $46.61M $32.65M $15.15M
YoY Change 167.93% 115.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.237M $4.768M $32.00K
YoY Change 12005.71% 14800.0%
Total Long-Term Liabilities $4.237M $4.768M $32.00K
YoY Change 12005.71% 14800.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.61M $32.65M $15.15M
Total Long-Term Liabilities $4.237M $4.768M $32.00K
Total Liabilities $50.85M $37.42M $15.18M
YoY Change 191.7% 146.51%
SHAREHOLDERS EQUITY
Retained Earnings -$354.2M -$311.5M
YoY Change 127.28%
Common Stock $694.9M $456.3M
YoY Change 14786.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $340.6M $144.0M $115.3M
YoY Change
Total Liabilities & Shareholders Equity $391.5M $181.4M $130.5M
YoY Change 270.64% 39.08%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$42.70M -$53.76M -$59.59M
YoY Change 50.66% -9.79% 76.87%
Depreciation, Depletion And Amortization $182.0K $165.0K $10.00K
YoY Change 727.27% 1550.0%
Cash From Operating Activities -$49.70M -$43.08M -$20.87M
YoY Change 75.96% 106.46% -24.97%
INVESTING ACTIVITIES
Capital Expenditures $620.0K -$459.0K -$153.0K
YoY Change -433.33% 200.0%
Acquisitions
YoY Change
Other Investing Activities -$227.6M $84.50M -$49.05M
YoY Change -7685.33% -272.26%
Cash From Investing Activities -$228.2M $84.04M -$49.21M
YoY Change -8208.74% -270.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $135.0M
YoY Change 350.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 232.2M 0.000 131.7M
YoY Change -21899.25% -100.0% 188.39%
NET CHANGE
Cash From Operating Activities -49.70M -43.08M -20.87M
Cash From Investing Activities -228.2M 84.04M -49.21M
Cash From Financing Activities 232.2M 0.000 131.7M
Net Change In Cash -45.72M 40.96M 61.58M
YoY Change 72.54% -33.48% 245.18%
FREE CASH FLOW
Cash From Operating Activities -$49.70M -$43.08M -$20.87M
Capital Expenditures $620.0K -$459.0K -$153.0K
Free Cash Flow -$50.32M -$42.62M -$20.71M
YoY Change 79.33% 105.77% -25.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001658551
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Amendment Flag
AmendmentFlag
false
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
54859000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
45927000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8336000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5392000
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41199
dei Entity Registrant Name
EntityRegistrantName
Amylyx Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4600503
dei Entity Address Address Line1
EntityAddressAddressLine1
43 Thorndike St.
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
682-0917
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
AMLX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66256218
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107734000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50191000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
137000
CY2022Q3 us-gaap Inventory Net
InventoryNet
563000
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
570000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3441000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
172199000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
104951000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2118000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
474000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
719000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
189000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5951000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
456000
CY2022Q3 us-gaap Assets
Assets
181443000
CY2021Q4 us-gaap Assets
Assets
105614000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7052000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4372000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23605000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13024000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1990000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32647000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17396000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4768000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
35000
CY2022Q3 us-gaap Liabilities
Liabilities
37415000
CY2021Q4 us-gaap Liabilities
Liabilities
17431000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
56500000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58533226
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58533226
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7020487
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7020487
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
456263000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4667000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-311516000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155845000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-725000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
144028000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-151168000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181443000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105614000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
345000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
345000
CY2021Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
285000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
285000
CY2022Q3 us-gaap Revenues
Revenues
345000
CY2021Q3 us-gaap Revenues
Revenues
285000
us-gaap Revenues
Revenues
345000
us-gaap Revenues
Revenues
285000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
172000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
172000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24914000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5214000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53881000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23142000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6757152
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12853000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70637000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30646000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29940000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10350000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
86284000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24012000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
55026000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
23203000
us-gaap Costs And Expenses
CostsAndExpenses
157093000
us-gaap Costs And Expenses
CostsAndExpenses
54658000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-54681000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22918000
us-gaap Operating Income Loss
OperatingIncomeLoss
-156748000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54373000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
601000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1134000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
amlx Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
5228000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
199000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-227000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
138000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
800000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-224000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1272000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-155476000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59587000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-125000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
195000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-53756000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-23142000
us-gaap Net Income Loss
NetIncomeLoss
-155671000
us-gaap Net Income Loss
NetIncomeLoss
-59587000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.42
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.20
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58533226
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58533226
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
669040
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6757152
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56163194
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56163194
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6477140
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6477140
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-53756000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-23142000
us-gaap Net Income Loss
NetIncomeLoss
-155671000
us-gaap Net Income Loss
NetIncomeLoss
-59587000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-559000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-569000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
30000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-5000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-165000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-5000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-529000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-734000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54285000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23143000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-156405000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59588000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-151168000
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
239351000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
196379000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4392000
CY2022Q1 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
-160000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-47848000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
240946000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
248000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5707000
CY2022Q2 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
-45000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-54067000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
192789000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5524000
CY2022Q3 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
-529000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-53756000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
144028000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-66725000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
586000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14523000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-80631000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
657000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-21922000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-101893000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
164000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
802000
CY2021Q3 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
-1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-23142000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-124070000
us-gaap Profit Loss
ProfitLoss
-155671000
us-gaap Profit Loss
ProfitLoss
-59587000
us-gaap Share Based Compensation
ShareBasedCompensation
15623000
us-gaap Share Based Compensation
ShareBasedCompensation
2045000
us-gaap Depreciation
Depreciation
305000
us-gaap Depreciation
Depreciation
30000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
196000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-23000
amlx Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
5228000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
137000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
563000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
61000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2879000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1764000
amlx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
1208000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
456000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-125000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2654000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-716000
amlx Increase Decrease In Accrued Expenses And Deferred Rent
IncreaseDecreaseInAccruedExpensesAndDeferredRent
10435000
amlx Increase Decrease In Accrued Expenses And Deferred Rent
IncreaseDecreaseInAccruedExpensesAndDeferredRent
8061000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-436000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-130174000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46555000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1906000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
167000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
154313000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
49053000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
145411000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10808000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49220000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
200897000
amlx Initial Public Offering Cost Paid
InitialPublicOfferingCostPaid
1518000
amlx Proceeds From Issuance Of Convertible Notes Related Parties
ProceedsFromIssuanceOfConvertibleNotesRelatedParties
14272000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
11887000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
134791000
amlx Issuance Costs Related To Conversion Of Convertible Notes
IssuanceCostsRelatedToConversionOfConvertibleNotes
50000
amlx Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
1527000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
248000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
198000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
199627000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
159571000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-572000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
58073000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
63800000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50380000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13066000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
108453000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76866000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
165000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-5000
amlx Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
43000
amlx Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
41000
amlx Right Of Use Assets And Liabilities Upon Asc842 Adoption
RightOfUseAssetsAndLiabilitiesUponAsc842Adoption
2201000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4958000
amlx Movement Of Deferred Offering Costs To Equity
MovementOfDeferredOfferingCostsToEquity
4518000
amlx Initial Public Offering Costs Included In Accounts Payable And Accrued Expenses
InitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
526000
amlx Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
570000
amlx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
189000
amlx Conversion Of Convertible Notes And Accrued Interest Into Redeemable Convertible Preferred Stock
ConversionOfConvertibleNotesAndAccruedInterestIntoRedeemableConvertiblePreferredStock
32548000
amlx Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering
ConversionOfPreferredStockToCommonStockUponInitialPublicOffering
239351000
us-gaap Income Taxes Paid
IncomeTaxesPaid
27000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of the Business</span><span style="text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amylyx Pharmaceuticals, Inc., together with its wholly owned subsidiaries, known as Amylyx or the Company, is a commercial-stage biopharmaceutical company with a mission to one day end the suffering caused by neurodegenerative diseases. The Company is focused on the development and potential global commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis, or ALS. In June 2022, AMX0035 received marketing authorization with conditions as ALBRIOZA by Health Canada for the treatment of ALS, and the Company launched ALBRIOZA in Canada on July 29, 2022. In September 2022, AMX0035 was approved as RELYVRIO by the U.S Food and Drug Administration, or FDA, for the treatment of ALS, and the Company launched RELYVRIO in the United States of America, or U.S., on October 24, 2022. The Company’s Marketing Authorisation Application, or MAA, for AMX0035 for the treatment of ALS remains under review by the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA. The Company is developing AMX0035 for other neurodegenerative diseases by leveraging its unique knowledge and relationships in the neurodegenerative space.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, the Company completed an initial public offering, or the IPO, in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,369,369</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. After deducting underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">196.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Upon the completion of IPO, all of the Company’s outstanding shares of preferred stock were converted into shares of its common stock. Refer to Note 15 for additional information regarding the Company's follow-on public offering of its common stock, completed in October 2022.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, the outcome of preclinical studies and clinical trials, market acceptance and the successful commercialization of ALBRIOZA which received marketing authorization with conditions in Canada in June 2022, and RELYVRIO, which was approved by the FDA in the U.S. in September 2022, potential difficulties with or delays in timing with respect to the regulatory approval processes of the EMA and other comparable foreign authorities, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, ability to secure additional capital to fund operations, and risks associated with the ongoing COVID-19 global pandemic. The COVID-19 pandemic may have an adverse impact on the Company’s operations, supply chains and distribution systems or those of its contractors, and increase expenses, including as a result of impacts associated with preventive and precautionary measures that are being taken, such as restrictions on travel and border crossings. The Company and its contractors may experience disruptions in supply of items that are essential for its research and development and commercial activities, including, for example, raw materials and bulk drug substances that the Company imports from Europe and Canada used in the manufacturing of AMX0035, and any future product candidates. In addition, the continued spread of COVID-19 has disrupted global healthcare and healthcare regulatory systems which could divert healthcare resources away from, or materially delay, approval by health authorities worldwide with respect to AMX0035 and any future product candidates. Furthermore, the Company’s ongoing and anticipated clinical trials may be negatively affected by the ongoing COVID-19 outbreak. Site initiation, patient enrollment and patient follow-up visits may be delayed, for example, due to prioritization of hospital resources toward the COVID-19 outbreak, travel restrictions, the inability to access sites for initiation and monitoring, and difficulties recruiting or retaining patients in the Company’s ongoing and planned clinical trials.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Economic uncertainty in various global markets, including the U.S. and Europe, caused by political instability and conflict, such as Russia's invasion of Ukraine, and economic challenges caused by the COVID-19 pandemic, have led to market disruptions, including significant volatility in commodity prices, credit and capital market instability and supply chain interruptions, which have caused record inflation globally. The Company's business, financial condition and results of operations could be materially and adversely affected by further negative impact on the global economy and capital markets resulting from these global economic conditions, particularly if such conditions are prolonged or worsen.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although, to date, our business has not been materially impacted by these global economic and geopolitical conditions, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which such instability could impact our business and results of operations. The extent and duration of these market disruptions, whether as a result of the military conflict between Russia and Ukraine, geopolitical tensions, record inflation or otherwise, are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this report.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that the Company will be able to successfully complete the development of, or receive additional regulatory approval for, any products developed, and if approved, that any products will be commercially viable. Any products resulting from the Company’s current research and development efforts will require significant additional research and development, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with Accounting Standards Update, or ASU, 2014-15,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the unaudited consolidated financial statements are issued.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its efforts to research and development and pre-commercialization activities, including recruiting management and technical staff, raising capital, producing materials for preclinical studies and clinical trials, and building infrastructure to support such activities. Expenses have primarily been for research and development and related general and administrative costs. The Company has generated revenues through five grants from ALS Association, ALS Finding a Cure Foundation, Cure Alzheimer’s Fund, Alzheimer’s Drug Discovery Foundation and Alzheimer’s Association, or Grantors. In addition to money received from its grants, the Company has also financed its operations through the public offering of its common stock, private sales of preferred stock, and convertible notes.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations since inception. As of September 30, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">311.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues initial sales of ALBRIOZA in Canada and launches RELYVRIO in the U.S., and continues to build capabilities and develop AMX0035, and any future product candidates. In the event that management does not achieve revenue anticipated in its operating plan, management has the ability and commitment to reduce operating expenses as necessary. The Company expects that its cash, cash equivalents and short-term investments as of September 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, together with the net proceeds from the Company's follow-on public offering, and product revenue from RELYVRIO and ALBRIOZA sales, will enable the Company to fund its ongoing operating expenses and capital expenditure requirements for at least the twelve-month period following the issuance of these condensed consolidated financial statements.</span></p>
CY2022Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
11369369
CY2022Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
19.00
CY2022Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
196400000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-311500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: reserves for variable consideration; recoverability of inventories, including those produced in preparation for product launches; determining the fair value of the Company’s common stock prior to the Company’s IPO in January 2022; determining the fair value of convertible notes; accrued expenses; stock option valuations; valuation allowance for deferred tax assets and research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 amlx Incremental Costs Expenses
IncrementalCostsExpenses
0
amlx Incremental Costs Expenses
IncrementalCostsExpenses
0
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
amlx Available For Sale Investments Contractual Maturity Period
AvailableForSaleInvestmentsContractualMaturityPeriod
P1Y
CY2021 amlx Available For Sale Investments Contractual Maturity Period
AvailableForSaleInvestmentsContractualMaturityPeriod
P1Y
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company entered into a new office space lease at 121 First Street in Cambridge, Massachusetts on January 10, 2022, for 36 months, with an option to extend the lease for 3 years.
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P36M
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5000000.0
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5000000.0
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
597000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2417000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2478000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1586000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
544000
us-gaap Operating Lease Cost
OperatingLeaseCost
1592000
CY2022Q3 us-gaap Lease Cost
LeaseCost
544000
us-gaap Lease Cost
LeaseCost
1592000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5951000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1990000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4768000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6758000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
476000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7554000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
796000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6758000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
amlx Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.073
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
532000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
541000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
555000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
563000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
476000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2667000
CY2022Q3 amlx Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
7505000
CY2021Q4 amlx Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
5666000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8994000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4280000
CY2022Q3 amlx Accrued Consulting And Other Professional Fess
AccruedConsultingAndOtherProfessionalFess
6750000
CY2021Q4 amlx Accrued Consulting And Other Professional Fess
AccruedConsultingAndOtherProfessionalFess
2820000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
356000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
258000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23605000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13024000
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
37710624
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
37107459
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
37107459
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
239351000
CY2021Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
416466000
CY2021Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
39474330
CY2021 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
0
CY2022Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
amlx Common Stock Number Of Voting Rights
CommonStockNumberOfVotingRights
1
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2021Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
us-gaap Dividends
Dividends
0
us-gaap Dividends
Dividends
0
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
41265000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
6782715
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
14.10
amlx Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm
P8Y9M18D
CY2022Q3 amlx Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue
95939000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
56500000
CY2022Q3 amlx Common Stock Shares Issued And Outstanding
CommonStockSharesIssuedAndOutstanding
58533226
CY2021Q4 amlx Common Stock Shares Issued And Outstanding
CommonStockSharesIssuedAndOutstanding
7020487
CY2022Q3 amlx Common Stock Authorized And Reserved For Future Issuance
CommonStockAuthorizedAndReservedForFutureIssuance
12319971
CY2021Q4 amlx Common Stock Authorized And Reserved For Future Issuance
CommonStockAuthorizedAndReservedForFutureIssuance
46257833
CY2022Q3 amlx Unreserved Common Stock Available For Future Issuance
UnreservedCommonStockAvailableForFutureIssuance
229146803
CY2021Q4 amlx Unreserved Common Stock Available For Future Issuance
UnreservedCommonStockAvailableForFutureIssuance
3221680
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5339011
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.54
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15627000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3968720
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.22
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
669040
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5961000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
63242
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.28
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8575449
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
137204000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1792734
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6000000.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4500000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
700000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5524000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
802000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15623000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2045000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5524000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
802000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15623000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2045000
amlx Number Of Operating Lease Agreements
NumberOfOperatingLeaseAgreements
2
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
700000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
200000
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
408000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
45000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
110000
CY2022Q3 us-gaap Inventory Net
InventoryNet
563000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
25700000

Files In Submission

Name View Source Status
0000950170-22-024465-index-headers.html Edgar Link pending
0000950170-22-024465-index.html Edgar Link pending
0000950170-22-024465.txt Edgar Link pending
0000950170-22-024465-xbrl.zip Edgar Link pending
amlx-20220930.htm Edgar Link pending
amlx-20220930.xsd Edgar Link pending
amlx-ex31_1.htm Edgar Link pending
amlx-ex31_2.htm Edgar Link pending
amlx-ex31_3.htm Edgar Link pending
amlx-ex32_1.htm Edgar Link pending
amlx-ex32_2.htm Edgar Link pending
amlx-ex32_3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
amlx-20220930_cal.xml Edgar Link unprocessable
amlx-20220930_def.xml Edgar Link unprocessable
amlx-20220930_lab.xml Edgar Link unprocessable
amlx-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amlx-20220930_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending